Boosting immune therapy for glioblastoma by controlling tumor inflammation
Official title: Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
Funded at Beckman Research Institute/city of Hope · NIH-11179213 · Data updated 2026-11-12
This project will try blocking the RAGE protein to help immune treatments work better for people with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $571,835 |
| NIH project number | 5R01NS134116-03 |
| Project ID | NIH-11179213 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with glioblastoma (GBM), including those with newly diagnosed or recurrent disease and individuals considered for immunotherapy, would be the ideal candidates.
✕Less likely to help
People without GBM, those whose tumors lack RAGE expression, or patients who cannot receive immunotherapy are unlikely to benefit from this work.
What this research studies
If you have glioblastoma, researchers plan to reduce inflammation in and around your tumor by targeting a protein called RAGE. They will combine RAGE blocking with immune-based therapies and study whether this helps immune cells reach and attack tumor cells. The team will use lab models, tumor samples, and treatment combinations to track changes in tumor growth and the tumor’s immune environment. Participation could involve samples or visits at the research center while scientists measure how the tumor and immune system respond.
Why it matters
Potential benefit: If successful, this approach could make immunotherapies work better against glioblastoma and potentially extend survival.
How similar studies have gone: Early laboratory and animal work showed that removing RAGE can improve immune responses in tumors, but clinical benefit in people has not yet been proven.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Badie, Behnam — Beckman Research Institute/city of Hope
- Study coordinator: Badie, Behnam
Related research
Other NIH-funded projects on the same topics.
-
Innate immune memory to help glioblastoma therapy
A Duke team is testing a weakened poliovirus treatment that could boost the body's immune attack on glioblastoma in patients who have the tumor.
-
Improving glioblastoma treatment by targeting tumor inflammation
This project looks at using a new approach to help brain cancer patients with glioblastoma respond better to immunotherapy by reducing harmful inflammation in the tumor.
-
Augmenting immunotherapy effects in glioma patients
A trial aims to see if adding DFMO to pembrolizumab can boost immune response and help people with grade 4 astrocytomas.
-
Enhancing treatment for glioblastoma by targeting tumor inflammation
This study is looking at a new way to make immunotherapy work better for people with glioblastoma, a tough type of brain cancer, by blocking a specific receptor that helps the tumor grow, and patients may have the chance to participate in trials testing this promising approach.
-
Investigating how glioma tumors respond to immunotherapy
This study is looking at why some people with glioblastoma, a type of brain cancer, benefit from immunotherapy while others don’t, by examining tumor samples and patient information to find clues that could help improve treatment for everyone.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.